Coherus Oncology to Host Webcast to Disclose Interim Tagmokitug Clinical Data on October 28, 2026

Coherus Oncology (CHRS) will release interim clinical data from its tagmokitug development program during a webcast on October 28, 2026.

Rhea-AI Summary

Coherus Oncology (CHRS) will release interim clinical data from its tagmokitug development program during a webcast on October 28, 2026. The program evaluates tagmokitug, an antibody targeting CCR8, with toripalimab in multiple solid tumors. Tagmokitug is currently in Phase 1b/2a studies in patients with advanced solid tumors.

Management will discuss the data from 4:30 p.m. to 6:00 p.m. Eastern Daylight Time, with invited clinical experts providing perspective. A live and archived webcast will be available in the Investors section of the company website, with accompanying materials available after the webcast.

Key Figures

Interim data disclosure: October 28, 2026

Interim data disclosure

October 28, 2026

Tagmokitug clinical data release

Key Terms

ccr8, phase 1b/2a, regulation fd

3 terms

ccr8 medical

"the cytolytic CCR8 antibody with toripalimab"

CCR8 is a protein on the surface of certain immune cells that acts like a GPS receiver, helping those cells move toward signals from inflamed tissue or tumors. Investors watch CCR8 because drugs that block or stimulate it can change how the immune system attacks disease, making it a promising target for cancer and autoimmune therapies; progress or setbacks in CCR8-focused treatments can materially affect a biotech’s valuation.

phase 1b/2a medical

"currently in Phase 1b/2a studies"

Phase 1b/2a is a combined early-stage clinical study that first tests safety and optimal dosing in a small group and then expands to look for initial signs that the drug works in the target patients. Think of it as a prototype test followed by a small pilot run: it helps companies decide whether to invest in larger, more expensive trials. Investors watch these results because they reduce scientific uncertainty and can sharply affect a drug’s value and development timeline.

regulation fd regulatory

"under Regulation FD"

Regulation FD is a rule that prevents company insiders, like executives, from sharing important information with some people before others get it. It matters because it helps ensure all investors have equal access to key news, making the stock market fairer and reducing chances of insider trading.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

REDWOOD CITY, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS) today announced that the Company will release interim clinical data related to its tagmokitug development program evaluating the cytolytic CCR8 antibody with toripalimab and multiple solid tumors on Wednesday, October 28, 2026. Coherus management will host a webcast from 4:30 p.m. to 6:00 p.m. Eastern Daylight Time to discuss the data and provide additional context. The company has invited key opinion leaders to join the webcast and provide their clinical perspective.

Webcast Information

When: Wednesday, October 28, 2026, from 4:30 p.m. to 6:00 p.m. Eastern Daylight Time.

To access the web ex, please pre-register through the following link to receive dial-in information and a personal PIN to access the live call: https://register-conf.media-server.com/register/BI40122fadb7e849969b28a667a784d035.

Webcast: https://edge.media-server.com/mmc/p/wygfpdac.

A live and archived webcast will be available on the “Investors” section of the Coherus website and accompanying materials will be available after the webcast at https://investors.coherus.com/events-presentations.  

Please log in approximately 15 minutes before the start of the webcast to ensure a timely connection.

Disclosure Information

Coherus uses the https://investors.coherus.com website as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. 

About Coherus Oncology

Coherus Oncology is a fully integrated commercial-stage innovative oncology company with an approved next-generation programmed death receptor-1 (“PD-1”) inhibitor, LOQTORZI^® (toripalimab-tpzi), and a pipeline that includes two mid-stage clinical candidates targeting liver, prostate, head & neck, colorectal and other cancers. The Company’s strategy is to grow sales of LOQTORZI in R/M Nasopharyngeal Carcinoma and advance the development of its two pipeline candidates in combination with LOQTORZI and through strategic partnerships.

Coherus’ innovative oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor response and improve outcomes for patients with cancer. Tagmokitug is a highly selective cytolytic anti-CCR8 antibody currently in Phase 1b/2a studies in patients with advanced solid tumors; including head and neck squamous cell carcinoma, colorectal cancer, gastric, gastro-esophageal-junction, esophageal adenocarcinoma and esophageal squamous cell carcinoma. Casdozokitug is a novel IL-27 antagonistic antibody currently being evaluated in a Phase 2 study in patients with first-line hepatocellular carcinoma.

LOQTORZI^® is a registered trademark of Coherus Oncology, Inc.
©2026 Coherus Oncology, Inc. All rights reserved.

Coherus Oncology Contact Information:

For Investors:
Carrie Graham
Vice President, Investor Relations & Advocacy
IR@coherus.com